Press release content from Business Wire. The AP news staff was not involved in its creation.
Ancora Heart Enrolls First Patient in the CORCINCH-HF Study
January 28, 2021 GMT
As the only completely transcatheter procedure to treat the enlarged left ventricle, the AccuCinch® Ventricular Restoration System is a fundamentally different and innovative device-based therapy designed to improve the structure and function of the heart and help bring relief to HF patients who remain symptomatic despite current guideline-directed medical care. (Graphic: Business Wire)
As the only completely transcatheter procedure to treat the enlarged left ventricle, the AccuCinch® Ventricular Restoration System is a fundamentally different and innovative device-based therapy designed to improve the structure and function of the heart and help bring relief to HF patients who remain symptomatic despite current guideline-directed medical care. (Graphic: Business Wire)
5 things nutrition experts want you to know about new federal dietary guidelines
sfgate.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sfgate.com Daily Mail and Mail on Sunday newspapers.
New dietary guidelines: 5 things nutrition experts want you to know - Lifestyle - Ridgecrest Daily Independent - Ridgecrest, CA
ridgecrestca.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from ridgecrestca.com Daily Mail and Mail on Sunday newspapers.
Startup banks on immune-system memory to tackle cancer
Loki Therapeutics is advancing research that leverages the immune system s ability to recall childhood vaccinations and direct it against cancer. The company s lead therapy candidate could enter phase 1 clinical trials this year.
Shares0
A New York-based startup is advancing what it believes is a novel approach to harnessing the immune system to fight cancer.
Many approaches rely in some way on training blank T-cells to recognize and attack cancer cells. Founded in 2020, Loki Therapeutics is based on research that makes cancer cells look like targets the body already recognizes.
The idea is essentially to “wake up” the immune system and reactivate T-cells that carry the memory of childhood vaccinations against diseases like tetanus, measles and mumps. The strategy reflects the fact that T cells carry the memory of those diseases long after shots are given.